LLY lilly.com: Enterprise Value-to-Revenue Ratio

lilly.com (LLY) - corporate logo

The Eli Lilly and Company (LLY) portfolio dominates the metabolic disorder treatment segment driven by surging demand for obesity drugs. However, geopolitical instability and the risks of patent expiration abroad create certain challenges. The EV/Sales trend reflects market momentum, where 15216.83 determines this parameter level. Ultimate success depends on FDA approvals and the scaling of innovative drug production.

LLY Eli Lilly and Co.: Company Value to Revenue in the range 11/23/2025 - 11/20/2026

Eli Lilly and Co. - analytical breakdowns and key metrics (LLY)

- price and consensus price forecast:
- company stock capitalization data:
- cash and cash flow indicators:
Initial company analysis:lilly.com - LLY
Flagship merchandise of Eli Lilly & Co.

This indicator determines the market value of the business relative to its annual turnover, completely excluding the impact of debt load. The formula compares enterprise value (EV) with revenue, allowing for an assessment of real cash flow generation efficiency without distortions from financial leverage. By analyzing the EV/Sales multiple trajectory, an investor sees the steady growth of Eli Lilly and Company (LLY), supported by low geopolitical risks and the global protection of pharmaceutical assets.